Stocks
Corcept Therapeutics Incorporated Financial Statements (CORT) |
||||||||||
| Corcept Therapeutics Incorporatedsmart-lab.ru | % | 2020 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 23.02.2021 | 15.11.2021 | 15.02.2022 | 28.02.2023 | 15.02.2024 | 30.10.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 353.9 | 353.9 | 366.0 | 401.9 | 482.4 | 628.6 | |||
| Operating Income, bln rub | 128.2 | 128.2 | 124.5 | 112.6 | 107.3 | 143.4 | ||||
| EBITDA, bln rub | ? | 128.2 | 130.4 | 124.5 | 112.6 | 108.3 | 144.6 | |||
| Net profit, bln rub | ? | 106.0 | 106.0 | 112.5 | 101.4 | 106.1 | 141.3 | |||
| OCF, bln rub | ? | 152.0 | 152.0 | 167.9 | 120.3 | 127.0 | 144.7 | |||
| CAPEX, bln rub | ? | 1.24 | 1.24 | 0.469 | 0.413 | 0.139 | 2.05 | |||
| FCF, bln rub | ? | 150.7 | 150.7 | 167.4 | 119.9 | 126.9 | 142.6 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 220.1 | 220.1 | 236.2 | 283.8 | 368.6 | 475.4 | ||||
| Cost of production, bln rub | 5.58 | 5.58 | 5.28 | 5.39 | 6.48 | 9.80 | ||||
| R&D, bln rub | 114.8 | 114.8 | 113.9 | 131.0 | 184.4 | 231.3 | ||||
| Interest expenses, bln rub | 0.000 | 0.000 | 0.000 | 3.56 | 0.000 | 3.58 | ||||
| Assets, bln rub | 571.7 | 571.7 | 423.8 | 583.4 | 621.5 | 784.3 | ||||
| Net Assets, bln rub | ? | 523.3 | 523.3 | 375.8 | 501.8 | 506.7 | 638.8 | |||
| Debt, bln rub | 2.55 | 2.55 | 0.526 | 1.14 | 0.151 | 6.79 | ||||
| Cash, bln rub | 476.9 | 476.9 | 335.8 | 436.6 | 368.2 | 380.3 | ||||
| Net debt, bln rub | -474.3 | -474.3 | -335.3 | -435.5 | -368.1 | -373.5 | ||||
| Ordinary share price, rub | 26.2 | 26.2 | 19.8 | 20.3 | 32.5 | 25.3 | ||||
| Number of ordinary shares, mln | 115.4 | 115.4 | 115.7 | 106.8 | 103.6 | 103.4 | ||||
| Market cap, bln rub | 3 019 | 3 019 | 2 290 | 2 169 | 3 364 | 2 614 | ||||
| EV, bln rub | ? | 2 545 | 2 545 | 1 955 | 1 733 | 2 996 | 2 241 | |||
| Book value, bln rub | 523 | 523 | 376 | 502 | 507 | 639 | ||||
| EPS, rub | ? | 0.92 | 0.92 | 0.97 | 0.95 | 1.02 | 1.37 | |||
| FCF/share, rub | 1.31 | 1.31 | 1.45 | 1.12 | 1.23 | 1.38 | ||||
| BV/share, rub | 4.53 | 4.53 | 3.25 | 4.70 | 4.89 | 6.18 | ||||
| EBITDA margin, % | ? | 36.2% | 36.9% | 34.0% | 28.0% | 22.5% | 23.0% | |||
| Net margin, % | ? | 30.0% | 30.0% | 30.7% | 25.2% | 22.0% | 22.5% | |||
| FCF yield, % | ? | 4.99% | 4.99% | 7.31% | 5.53% | 3.77% | 5.45% | |||
| ROE, % | ? | 20.3% | 20.3% | 29.9% | 20.2% | 20.9% | 22.1% | |||
| ROA, % | ? | 18.5% | 18.5% | 26.6% | 17.4% | 17.1% | 18.0% | |||
| P/E | ? | 28.5 | 28.5 | 20.4 | 21.4 | 31.7 | 18.5 | |||
| P/FCF | 20.0 | 20.0 | 13.7 | 18.1 | 26.5 | 18.3 | ||||
| P/S | ? | 8.53 | 8.53 | 6.26 | 5.40 | 6.97 | 4.16 | |||
| P/BV | ? | 5.77 | 5.77 | 6.09 | 4.32 | 6.64 | 4.09 | |||
| EV/EBITDA | ? | 19.9 | 19.5 | 15.7 | 15.4 | 27.7 | 15.5 | |||
| Debt/EBITDA | -3.70 | -3.64 | -2.69 | -3.87 | -3.40 | -2.58 | ||||
| R&D/CAPEX, % | 9 270% | 9 270% | 24 278% | 31 717% | 132 628% | 11 277% | ||||
| CAPEX/Revenue, % | 0.35% | 0.35% | 0.13% | 0.10% | 0.03% | 0.33% | ||||
| Corcept Therapeutics Incorporated shareholders | ||||||||||
